Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Prothionamide

What is Prothionamide?

CAS No: 14222-60-7

Prothionamide is a pharmacologically active or chemically reactive compound used in pharmaceutical manufacturing as an active ingredient, synthetic intermediate, or process reagent, requiring toxicological characterisation to establish protective occupational exposure limits. Available data from in vitro and in vivo studies are evaluated in a weight-of-evidence assessment to identify the critical study, the most sensitive adverse effect endpoint, and the applicable NOAEL or LOAEL that serves as the point of departure for PDE calculation. Data gaps are addressed through read-across from structurally related compounds, (Q)SAR predictions, or application of TTC defaults where scientifically justified.

PDE derivation for Prothionamide applies the composite uncertainty factor methodology: F1 accounts for interspecies pharmacokinetic and pharmacodynamic differences (default 12 for rat-to-human, refinable with toxicokinetic AUC bridging data), F2 covers intraspecies variability in the human population including sensitive subgroups (default 10), F3 a

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Prothionamide is a thioamide medicinal substance used in antimicrobial treatment. Its pharmacological activity and available toxicological evidence may inform assessment of potential exposure. Understanding the evidence and conditions of use helps support a documented, risk-based approach to handling. The specific conclusions should be grounded in documented evidence and the actual handling context.

A PDE or ADE sets a health-based limit on daily exposure to Prothionamide from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

An exposure limit may still be assessed for a chemical that is not a marketed drug when there is a defined need to manage occupational exposure or cross-contamination. The approach depends on the available toxicological information and may consider related compounds or structure-based evidence where scientifically justified. Assumptions and limitations should be documented rather than presented as established facts.

The assessment may consider repeat-dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, and pharmacological activity where relevant data are available. The critical endpoint is selected by evaluating the reliability and relevance of the evidence. Data gaps and assumptions should be documented so the basis for the health-based exposure limit is transparent.

Not automatically. A PDE or ADE is derived for a defined assessment context and route, often oral exposure when evaluating residual carryover into another product. Applying the value to inhalation or dermal exposure may require additional scientific justification. The report should clearly state its scope, route assumptions, and any limitations relevant to use.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Prothionamide in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

A PDE or ADE addresses an acceptable daily exposure in a defined context, commonly to support assessment of residual carryover between products. An OEL addresses exposure in the workplace, often focusing on inhalation over a specified period. These values serve different purposes and should not be treated as interchangeable without a scientific justification.

An occupational exposure band can help categorize a substance and guide proportionate containment and handling controls. It does not automatically replace a substance-specific occupational exposure limit. Whether an OEL is available and how the band is assigned depend on the evidence and the framework used. The report should clearly distinguish the purpose and limitations of each.

The physical form and handling conditions of Prothionamide can influence how exposure may occur. For example, powder handling may create different inhalation considerations from transferring a solution, while process steps and containment also matter. The occupational assessment should use the available information about the material and actual tasks rather than assume that one form represents every scenario.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Prothionamide to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo